NCT00851864View on ClinicalTrials.gov

Safety and Efficacy of Therapeutic Anticoagulation With Tinzaparin During Pregnancy Via Weight-based Dosing

PHASE4CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

October 31, 2010

Study Completion Date

May 31, 2011

Conditions
Venous Thromboembolism
Interventions
DRUG

Tinzaparin

"LMWH (tinzaparin-Innohep, Leo Pharma A/S) 175 anti-factor Xa units per kilogram of body weight sub-cutaneously once daily.~Treatment will be done for the duration of the pregnancy."

Trial Locations (1)

T2N 4N1

Calgary Health Region, Calgary

Sponsors

Collaborators (1)

LEO Pharma
All Listed Sponsors
collaborator

LEO Pharma

INDUSTRY

lead

University of Calgary

OTHER